Biotech Values

[DewDiligence]

Further to the short thesis for ARIA:

The instances of pumping by ARIA executives continue to expand. We saw in #msg-68259377 how management hyped the fact that the Ponatanib NDA was “already being written,” notwithstanding the fact that all drug/biotech companies prepare certain modules of an NDA well in advance of the actual submission.

Now, we have the tautological tout in #msg-69013537 that “no patient failed” in the PACE trial if they were a complete responder.

While the kind of behavior cited above is far from probative, in my experience it does have a mild negative correlation with ultimate success.